Entry Into a Material Definitive Agreement. On September 11, 2026, BioVie Inc., a Nevada corporation (the “Company”), entered into a sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”), pursuant to which the Company may issue and sell from time to time, to or through the Agent, shares of the Company’s Class A common stock, par value $0.0001 per share (“Common Stock”), having an aggregate offering price of up to $6,464,341 (the “Placement Shares”). The Pl…

Entry Into a Material Definitive Agreement On August 7, 2025, BioVie Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with ThinkEquity LLC, as the sole underwriter (the “ Underwriter ”), in connection with the issuance and sale (the “ Offering ”) of 5,620,000 units (the “ Units ”) and 380,000 pre-funded units (the “ Pre-Funded Units ”), resulting in net proceeds of approximately $10.4 million, after deducting underwriting discounts and commissions…

The offer and sale of the Underwriter’s Warrants have not been registered under the Securities Act and were instead offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and/or Rule 506(b) promulgated thereunder. The Underwriter’s Warrants and the shares of Common Stock underlying the Underwriter’s Warrants may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state sec…

Director — Amy S. Chappell, MD, FAAN and Kameel D. Farag: The Board of Directors increased its size and appointed two new directors.

Material Modification to Rights of Security Holders. As previously reported, at a special meeting of stockholders of BioVie Inc. ( the “Company”) held on June 23, 2025 (the “Special Meeting”), the Company’s stockholders approved a proposal authorizing the board of directors of the Company (the “Board”), in its sole discretion, prior to the one-year anniversary of the Special Meeting, to effect a reverse stock split of the outstanding shares of the Company’s Class A common stock (“Common Stock…

Director — Dr. Robert Hariri: Dr. Robert Hariri resigned from the Board of Directors.

Other Events. Registered Direct Offering and Concurrent Private Placement On October 28, 2024, the Company announced that it had closed the previously announced registered direct offering of 1,146,000 shares (the “ Shares ”) of its Class A common stock, par value $0.0001 per share (the “ Common Stock ”), at a purchase price of $2.83 per Share (the “ Offering ”). The gross proceeds to the Company from the Offering were approximately $3,243,180, before deducting placement agent fees and offerin…

Regulation FD Disclosure. On October 28, 2024, the Company issued a press release announcing the Offering. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, and…

Entry Into a Material Definitive Agreement On October 28, 2024, BioVie Inc. (the “ Company ”) entered into a placement agent agreement (the “ Agreement ”) with ThinkEquity LLC, as the placement agent (the “ Placement Agent ”), in connection with the issuance and sale (the “ Offering ”) directly to various investors (the “ Investors ”) of up to 1,146,000 shares (the “ Shares ”) of the Company’s Class A common stock, par value $0.0001 per share (the “ Common Stock ”), at a public offering price…

The Warrants and the Warrant Shares were offered to the Investors pursuant to an exemption from the registration requirements of the Securities Act provided under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder. The sale of such securities did not involve a public offering and was made without general solicitation or general advertising. Accordingly, the Warrants and the Warrant Shares have not been registered under the Securities Act and the Warra…

Regulation FD Disclosure. On October 23, 2024, the Company issued a press release announcing the Offering. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, and…

Other Events. Registered Direct Offering and Concurrent Private Placement On October 23, 2024, the Company announced that it had closed the previously announced registered direct offering of 2,667,000 shares (the “ Shares ”) of its Class A common stock, par value $0.0001 per share (the “ Common Stock ”), at a purchase price of $2.25 per Share (the “ Registered Direct Offering ”), and a concurrent private placement of warrants to purchase up to 2,667,000 shares of Common Stock (the “ Warrants…

Entry Into a Material Definitive Agreement On October 23, 2024, BioVie Inc. (the “ Company ”) entered into a placement agent agreement (the “ Agreement ”) with ThinkEquity LLC, as the placement agent (the “ Placement Agent ”), in connection with the issuance and sale (the “ Offering ”) directly to various investors (the “ Investors ”) of up to 2,667,000 shares (the “ Shares ”) of the Company’s Class A common stock, par value $0.0001 per share (the “ Common Stock ”), at a public offering price…

The Warrants and the Warrant Shares were offered to the Investors pursuant to an exemption from the registration requirements of the Securities Act provided under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder. The sale of such securities did not involve a public offering and was made without general solicitation or general advertising. Accordingly, the Warrants and the Warrant Shares have not been registered under the Securities Act and the Warra…

Regulation FD Disclosure. On October 21, 2024, the Company issued a press release announcing the Offering. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, and…

The Warrants and the Warrant Shares were offered to the Investors pursuant to an exemption from the registration requirements of the Securities Act provided under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder. The sale of such securities did not involve a public offering and was made without general solicitation or general advertising. Accordingly, the Warrants and the Warrant Shares have not been registered under the Securities Act and the Warra…

Entry Into a Material Definitive Agreement On October 21, 2024, BioVie Inc. (the “ Company ”) entered into a placement agent agreement (the “ Agreement ”) with ThinkEquity LLC, as the placement agent (the “ Placement Agent ”), in connection with the issuance and sale (the “ Offering ”) directly to various investors (the “ Investors ”) of up to 4,443,000 shares (the “ Shares ”) of the Company’s Class A common stock, par value $0.0001 per share (the “ Common Stock ”), at a public offering price…

Entry Into a Material Definitive Agreement On September 23, 2024, BioVie Inc. (the “ Company ”) entered into a placement agent agreement (the “ Agreement ”) with ThinkEquity LLC, as the placement agent (the “ Placement Agent ”), in connection with the issuance and sale (the “ Offering ”) directly to various investors (the “ Investors ”) of up to 1,960,800 shares (the “ Shares ”) of the Company’s class A common stock, par value $0.0001 per share (the “ Common Stock ”), at a public offering pri…

Regulation FD Disclosure. On September 23, 2024, the Company issued a press release announcing the Offering. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. On September 23, 2024, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached hereto as Exhibit 99.2 and incorporated by reference herein. The information in this Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, is…

Material Modification to Rights of Security Holders. To the extent required by

of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in

Director — Steve Gorlin: Mr. Gorlin resigned as a director of the Company, effective immediately.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 18, 2024, BioVie Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Nasdaq Listing Rule 5550(a)(2). Under Nasdaq Listing…

Other Events. On March 11, 2024, BioVie Inc. (the “Company”) issued a press release announcing updates on its drug candidate pipeline and near-term clinical priorities. The Company is filing a copy of the press release, which is attached hereto as Exhibit 99.1 and incorporated herein by reference. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements, which may be identified by words such as “expect,” “look forward to,” “anticipate” “intend,” “plan,” “…

Entry Into a Material Definitive Agreement On March 4, 2024, BioVie Inc. (the “ Company ”) entered into a placement agent agreement (the “ Agreement ”) with ThinkEquity LLC, as the placement agent (the “ Placement Agent ”), in connection with the issuance and sale (the “ Offering ”) directly to various investors (the “ Investors ”) of up to 21,000,000 shares (the “ Shares ”) of the Company’s class A common stock, par value $0.0001 per share (the “ Common Stock ”), at a public offering price t…